590 results
8-K
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
.
Description
Press release of Bristol-Myers Squibb Company dated April 25, 2024
Presentation Materials of Bristol-Myers Squibb Company dated April 25, 2024
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
unable to register can access the live conference call by dialing in the U.S. toll-free 1-833-816-1116 or international +1 412-317-0705. Materials related
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
Materials
Soliciting Material under §240.14a-12
Bristol-Myers Squibb Company
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing … materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
April 2024 Proxy Season Update
2 Our
DEFA14A
BMY
Bristol-Myers Squibb Co.
28 Mar 24
Additional proxy soliciting materials
5:17pm
Additional Materials
Soliciting Material under §240.14a-12
Bristol-Myers Squibb Company
(Name of Registrant as Specified In Its Charter)
(Name of Person(s … with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
SC TO-T/A
EX-99
59hr1 f37
23 Feb 24
Third party tender offer statement (amended)
7:34am
8-K
EX-99.1
f6xdnatb5j3jea9os4af
14 Feb 24
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
4:32pm
SC TO-T/A
60kostpf8j pd
12 Feb 24
Third party tender offer statement (amended)
7:34am
SC TO-T/A
EX-99
4pgf39236h1951w951
12 Feb 24
Third party tender offer statement (amended)
7:34am
8-K
65uo6adl14vcy68
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am